| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD8958 | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.016 | 0.8 |
| mRNA | Nutlin-3a (-) | GDSC1000 | pan-cancer | AAC | -0.0096 | 0.8 |
| mRNA | ceranib-2 | CTRPv2 | pan-cancer | AAC | 0.0086 | 0.8 |
| mRNA | GDC-0879 | CTRPv2 | pan-cancer | AAC | -0.0093 | 0.8 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | -0.0083 | 0.8 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0095 | 0.8 |
| mRNA | AS605240 | GDSC1000 | pan-cancer | AAC | 0.0089 | 0.8 |
| mRNA | Imatinib | CTRPv2 | pan-cancer | AAC | -0.0092 | 0.8 |
| mRNA | XL765 | CTRPv2 | pan-cancer | AAC | -0.0096 | 0.8 |